630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models

• Peter Lamb,
• Seema Kantak,
• Bryan Glaser,
• Justin Wetter,
• Bee-Cheng Sim,
• Jeff Higaki,
• Jacob Beal,
• Sara Ollerman,
• Dileep Pulukkunat,
• Mandar Bawadekar,
• Charles Kaplan,
• Bonnie Hammer

Affiliations

Peter Lamb

1Exelixis, Inc., Alameda, CA, USA

Seema Kantak

1Exelixis, Inc., Alameda, CA, USA

Bryan Glaser

2Invenra, Inc., Madison, WI, USA

Justin Wetter

2Invenra, Inc., Madison, WI, USA

Bee-Cheng Sim

1Exelixis, Inc., Alameda, CA, USA

Jeff Higaki

1Exelixis, Inc., Alameda, CA, USA

Jacob Beal

2Invenra, Inc., Madison, WI, USA

Sara Ollerman

2Invenra, Inc., Madison, WI, USA

Dileep Pulukkunat

2Invenra, Inc., Madison, WI, USA

Mandar Bawadekar

2Invenra, Inc., Madison, WI, USA

Charles Kaplan

1Exelixis, Inc., Alameda, CA, USA

Bonnie Hammer

2Invenra, Inc., Madison, WI, USA